Authors: COMANDONE A LEONE L OLIVA C FRUSTACI S MONTELEONE M COLUSSI AM DALCANTON O BERGNOLO P BOGLIONE A BUMMA C

Citation: A. Comandone et al., PHARMACOKINETICS OF IFOSFAMIDE ADMINISTERED ACCORDING TO 3 DIFFERENT SCHEDULES IN METASTATIC SOFT-TISSUE AND BONE SARCOMAS, Journal of chemotherapy, 10(5), 1998, pp. 385-393

Authors: COMANDONE A TSERONI V FILIPPI A PASQUINO M DALCANTON O BERGNOLO P BOGLIONE A TROTTI AB

Citation: A. Comandone et al., ADJUVANT CHEMORADIOTHERAPY IN THE TREATMENT OF RECTAL-CANCER, Annals of oncology, 9, 1998, pp. 186-186

Authors: AIROLDI M DECRESCENZO A DALCANTON O ROSTI G AME C DONADIO M BUMMA C

Citation: M. Airoldi et al., HIGH-DOSE CHEMOTHERAPY (HDC) WITH HEMATOPOIETIC PROGENITOR-CELL (HPC)SUPPORT IN PATIENTS WITH RECURRENT UNDIFFERENTIATED NASOPHARYNGEAL CANCER (UNPC), Bone marrow transplantation, 21, 1998, pp. 647-647

Authors: DECRESCENZO A PEZZANA A AIROLDI M AME C MALVASO M SILLANO M GIROTTO E PETRACHI MN MANCINO MV AMISANO S DALCANTON O SABER B BUMMA C

Citation: A. Decrescenzo et al., HIGH-DOSE CHEMOTHERAPY (HD-CT) WITH PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION (PBCP) IN SOLID TUMORS - NUTRITIONAL-EVALUATION, Bone marrow transplantation, 21, 1998, pp. 807-807

Authors: COMANDONE A BOGLIONE A DALCANTON O BERGNOLO P OLIVA C BUMMA C

Citation: A. Comandone et al., IFOSFAMIDE (IFO) IN CONTINUOUS-INFUSION (CI) FOR 21 DAYS AS 2ND LINE THERAPY IN ADVANCED SARCOMAS - A PHASE-I STUDY, European journal of cancer, 33, 1997, pp. 499-499

Authors: DONADIO M MANZIN E DALCANTON O BERARDENGO E BUMMA C

Citation: M. Donadio et al., EVOLUTION OF BIOLOGICAL PARAMETERS IN PATIENTS WITH BREAST-CANCER TREATED WITH PRIMARY CHEMOTHERAPY, European journal of cancer, 33, 1997, pp. 897-897